Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

An informed capability assessment of different geographies, such as North America, Europe and Asia Pacific, is based on a variety of relevant parameters, such as number of CMOs, number of clinical sites, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of CMOs offering manufacturing for API / FDF, number of CMOs having capabilities for clinical / commercial manufacturing, current demand for peptide therapeutics and installed manufacturing capacity in a particular region. Where, North America emerged as the most prominent region as per the above-mentioned parameters. It is worth highlighting that across all the regions, the peptide manufacturing facilities are capable of providing manufacturing services at the clinical scale.

The figure presents the analytical distribution of the above-mentioned parameters in North America.


Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe